Intrinsic value of Intuitive Surgical - ISRG

Previous Close

$369.58

  Intrinsic Value

$261.68

stock screener

  Rating & Target

sell

-29%

Previous close

$369.58

 
Intrinsic value

$261.68

 
Up/down potential

-29%

 
Rating

sell

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of ISRG stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 41.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  13.42
  18.00
  16.70
  15.53
  14.48
  13.53
  12.68
  11.91
  11.22
  10.60
  10.04
  9.53
  9.08
  8.67
  8.30
  7.97
  7.68
  7.41
  7.17
  6.95
  6.76
  6.58
  6.42
  6.28
  6.15
  6.04
  5.93
  5.84
  5.76
  5.68
  5.61
Revenue, $m
  2,704
  3,191
  3,724
  4,302
  4,925
  5,591
  6,300
  7,050
  7,841
  8,671
  9,542
  10,451
  11,400
  12,389
  13,418
  14,488
  15,600
  16,756
  17,957
  19,205
  20,502
  21,851
  23,255
  24,715
  26,236
  27,820
  29,470
  31,191
  32,987
  34,860
  36,817
Variable operating expenses, $m
 
  1,142
  1,329
  1,532
  1,751
  1,986
  2,235
  2,499
  2,777
  3,069
  3,375
  3,674
  4,008
  4,356
  4,717
  5,093
  5,484
  5,891
  6,313
  6,752
  7,208
  7,682
  8,176
  8,689
  9,224
  9,780
  10,361
  10,966
  11,597
  12,256
  12,944
Fixed operating expenses, $m
 
  827
  848
  869
  891
  913
  936
  959
  983
  1,008
  1,033
  1,059
  1,085
  1,112
  1,140
  1,169
  1,198
  1,228
  1,259
  1,290
  1,322
  1,355
  1,389
  1,424
  1,460
  1,496
  1,534
  1,572
  1,611
  1,651
  1,693
Total operating expenses, $m
  1,759
  1,969
  2,177
  2,401
  2,642
  2,899
  3,171
  3,458
  3,760
  4,077
  4,408
  4,733
  5,093
  5,468
  5,857
  6,262
  6,682
  7,119
  7,572
  8,042
  8,530
  9,037
  9,565
  10,113
  10,684
  11,276
  11,895
  12,538
  13,208
  13,907
  14,637
Operating income, $m
  945
  1,222
  1,547
  1,900
  2,282
  2,692
  3,129
  3,592
  4,081
  4,595
  5,134
  5,718
  6,307
  6,921
  7,560
  8,225
  8,917
  9,637
  10,385
  11,163
  11,972
  12,814
  13,690
  14,602
  15,553
  16,543
  17,576
  18,654
  19,779
  20,953
  22,181
EBITDA, $m
  1,037
  1,318
  1,656
  2,024
  2,421
  2,846
  3,300
  3,781
  4,289
  4,823
  5,383
  5,969
  6,581
  7,218
  7,882
  8,573
  9,292
  10,039
  10,816
  11,624
  12,464
  13,338
  14,248
  15,195
  16,182
  17,211
  18,283
  19,402
  20,570
  21,790
  23,064
Interest expense (income), $m
  0
  0
  4
  9
  15
  20
  26
  33
  40
  47
  55
  63
  71
  80
  89
  98
  108
  118
  129
  140
  151
  163
  175
  188
  202
  215
  230
  245
  261
  277
  294
Earnings before tax, $m
  981
  1,222
  1,542
  1,891
  2,268
  2,672
  3,103
  3,559
  4,041
  4,548
  5,079
  5,656
  6,236
  6,841
  7,472
  8,127
  8,810
  9,519
  10,256
  11,023
  11,821
  12,651
  13,515
  14,414
  15,351
  16,328
  17,346
  18,409
  19,518
  20,676
  21,886
Tax expense, $m
  245
  330
  416
  511
  612
  721
  838
  961
  1,091
  1,228
  1,371
  1,527
  1,684
  1,847
  2,017
  2,194
  2,379
  2,570
  2,769
  2,976
  3,192
  3,416
  3,649
  3,892
  4,145
  4,408
  4,683
  4,970
  5,270
  5,583
  5,909
Net income, $m
  736
  892
  1,126
  1,380
  1,656
  1,950
  2,265
  2,598
  2,950
  3,320
  3,708
  4,129
  4,552
  4,994
  5,454
  5,933
  6,431
  6,949
  7,487
  8,047
  8,629
  9,235
  9,866
  10,522
  11,206
  11,919
  12,663
  13,438
  14,248
  15,093
  15,977

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  2,555
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  6,487
  4,638
  5,412
  6,253
  7,158
  8,126
  9,156
  10,247
  11,396
  12,604
  13,869
  15,191
  16,570
  18,007
  19,502
  21,058
  22,674
  24,354
  26,100
  27,914
  29,800
  31,761
  33,801
  35,923
  38,133
  40,436
  42,835
  45,336
  47,946
  50,669
  53,513
Adjusted assets (=assets-cash), $m
  3,932
  4,638
  5,412
  6,253
  7,158
  8,126
  9,156
  10,247
  11,396
  12,604
  13,869
  15,191
  16,570
  18,007
  19,502
  21,058
  22,674
  24,354
  26,100
  27,914
  29,800
  31,761
  33,801
  35,923
  38,133
  40,436
  42,835
  45,336
  47,946
  50,669
  53,513
Revenue / Adjusted assets
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
Average production assets, $m
  486
  574
  670
  774
  886
  1,006
  1,134
  1,269
  1,411
  1,561
  1,718
  1,881
  2,052
  2,230
  2,415
  2,608
  2,808
  3,016
  3,232
  3,457
  3,690
  3,933
  4,186
  4,449
  4,722
  5,008
  5,305
  5,614
  5,938
  6,275
  6,627
Working capital, $m
  2,653
  115
  134
  155
  177
  201
  227
  254
  282
  312
  344
  376
  410
  446
  483
  522
  562
  603
  646
  691
  738
  787
  837
  890
  944
  1,002
  1,061
  1,123
  1,188
  1,255
  1,325
Total debt, $m
  0
  126
  265
  416
  579
  754
  939
  1,135
  1,342
  1,560
  1,787
  2,025
  2,274
  2,532
  2,801
  3,081
  3,372
  3,675
  3,989
  4,316
  4,655
  5,008
  5,375
  5,757
  6,155
  6,569
  7,001
  7,452
  7,921
  8,411
  8,923
Total liabilities, $m
  709
  835
  974
  1,125
  1,288
  1,463
  1,648
  1,844
  2,051
  2,269
  2,496
  2,734
  2,983
  3,241
  3,510
  3,790
  4,081
  4,384
  4,698
  5,025
  5,364
  5,717
  6,084
  6,466
  6,864
  7,278
  7,710
  8,161
  8,630
  9,120
  9,632
Total equity, $m
  5,778
  3,803
  4,438
  5,127
  5,869
  6,664
  7,508
  8,402
  9,345
  10,335
  11,372
  12,457
  13,588
  14,766
  15,992
  17,267
  18,593
  19,970
  21,402
  22,889
  24,436
  26,044
  27,717
  29,457
  31,269
  33,157
  35,124
  37,176
  39,316
  41,549
  43,881
Total liabilities and equity, $m
  6,487
  4,638
  5,412
  6,252
  7,157
  8,127
  9,156
  10,246
  11,396
  12,604
  13,868
  15,191
  16,571
  18,007
  19,502
  21,057
  22,674
  24,354
  26,100
  27,914
  29,800
  31,761
  33,801
  35,923
  38,133
  40,435
  42,834
  45,337
  47,946
  50,669
  53,513
Debt-to-equity ratio
  0.000
  0.030
  0.060
  0.080
  0.100
  0.110
  0.130
  0.140
  0.140
  0.150
  0.160
  0.160
  0.170
  0.170
  0.180
  0.180
  0.180
  0.180
  0.190
  0.190
  0.190
  0.190
  0.190
  0.200
  0.200
  0.200
  0.200
  0.200
  0.200
  0.200
  0.200
Adjusted equity ratio
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820
  0.820

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  736
  892
  1,126
  1,380
  1,656
  1,950
  2,265
  2,598
  2,950
  3,320
  3,708
  4,129
  4,552
  4,994
  5,454
  5,933
  6,431
  6,949
  7,487
  8,047
  8,629
  9,235
  9,866
  10,522
  11,206
  11,919
  12,663
  13,438
  14,248
  15,093
  15,977
Depreciation, amort., depletion, $m
  92
  97
  109
  123
  138
  154
  171
  189
  208
  228
  249
  251
  274
  297
  322
  348
  374
  402
  431
  461
  492
  524
  558
  593
  630
  668
  707
  749
  792
  837
  884
Funds from operations, $m
  1,040
  989
  1,235
  1,504
  1,794
  2,105
  2,436
  2,787
  3,158
  3,548
  3,957
  4,379
  4,826
  5,291
  5,776
  6,281
  6,805
  7,351
  7,918
  8,508
  9,121
  9,760
  10,424
  11,115
  11,836
  12,587
  13,370
  14,187
  15,040
  15,930
  16,861
Change in working capital, $m
  -3
  18
  19
  21
  22
  24
  26
  27
  28
  30
  31
  33
  34
  36
  37
  39
  40
  42
  43
  45
  47
  49
  51
  53
  55
  57
  59
  62
  65
  67
  70
Cash from operations, $m
  1,043
  971
  1,216
  1,483
  1,771
  2,081
  2,411
  2,760
  3,130
  3,518
  3,926
  4,347
  4,792
  5,256
  5,739
  6,242
  6,765
  7,309
  7,875
  8,463
  9,075
  9,711
  10,373
  11,063
  11,781
  12,530
  13,310
  14,125
  14,975
  15,863
  16,790
Maintenance CAPEX, $m
  0
  -65
  -77
  -89
  -103
  -118
  -134
  -151
  -169
  -188
  -208
  -229
  -251
  -274
  -297
  -322
  -348
  -374
  -402
  -431
  -461
  -492
  -524
  -558
  -593
  -630
  -668
  -707
  -749
  -792
  -837
New CAPEX, $m
  -54
  -88
  -96
  -104
  -112
  -120
  -128
  -135
  -142
  -150
  -157
  -164
  -171
  -178
  -185
  -193
  -200
  -208
  -216
  -225
  -234
  -243
  -253
  -263
  -274
  -285
  -297
  -310
  -323
  -337
  -352
Cash from investing activities, $m
  -1,279
  -153
  -173
  -193
  -215
  -238
  -262
  -286
  -311
  -338
  -365
  -393
  -422
  -452
  -482
  -515
  -548
  -582
  -618
  -656
  -695
  -735
  -777
  -821
  -867
  -915
  -965
  -1,017
  -1,072
  -1,129
  -1,189
Free cash flow, $m
  -236
  818
  1,044
  1,290
  1,556
  1,843
  2,149
  2,474
  2,818
  3,181
  3,561
  3,954
  4,370
  4,804
  5,257
  5,728
  6,217
  6,727
  7,257
  7,807
  8,380
  8,976
  9,596
  10,242
  10,914
  11,615
  12,346
  13,108
  13,903
  14,734
  15,601
Issuance/(repayment) of debt, $m
  0
  126
  139
  151
  163
  174
  185
  196
  207
  217
  228
  238
  248
  259
  269
  280
  291
  302
  314
  327
  339
  353
  367
  382
  398
  414
  432
  450
  470
  490
  512
Issuance/(repurchase) of shares, $m
  538
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  559
  126
  139
  151
  163
  174
  185
  196
  207
  217
  228
  238
  248
  259
  269
  280
  291
  302
  314
  327
  339
  353
  367
  382
  398
  414
  432
  450
  470
  490
  512
Total cash flow (excl. dividends), $m
  322
  944
  1,183
  1,441
  1,719
  2,017
  2,334
  2,670
  3,025
  3,398
  3,789
  4,192
  4,618
  5,063
  5,526
  6,008
  6,508
  7,029
  7,571
  8,134
  8,720
  9,329
  9,963
  10,624
  11,312
  12,029
  12,778
  13,558
  14,373
  15,224
  16,113
Retained Cash Flow (-), $m
  -1,458
  -580
  -635
  -689
  -742
  -794
  -845
  -894
  -943
  -990
  -1,037
  -1,084
  -1,131
  -1,178
  -1,226
  -1,275
  -1,326
  -1,378
  -1,431
  -1,488
  -1,546
  -1,608
  -1,673
  -1,741
  -1,812
  -1,888
  -1,967
  -2,051
  -2,140
  -2,233
  -2,332
Prev. year cash balance distribution, $m
 
  2,555
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  2,919
  548
  752
  977
  1,223
  1,490
  1,776
  2,083
  2,408
  2,751
  3,108
  3,487
  3,885
  4,300
  4,732
  5,183
  5,652
  6,139
  6,646
  7,173
  7,721
  8,291
  8,883
  9,500
  10,142
  10,810
  11,507
  12,233
  12,991
  13,781
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  2,798
  502
  654
  804
  948
  1,081
  1,200
  1,302
  1,383
  1,442
  1,476
  1,488
  1,477
  1,443
  1,389
  1,317
  1,230
  1,131
  1,023
  911
  799
  688
  582
  484
  395
  315
  247
  189
  142
  104
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Intuitive Surgical, Inc. (Intuitive) designs, manufactures and markets da Vinci Surgical Systems, and related instruments and accessories. The Company's da Vinci Surgical System consists of a surgeon's console, a patient-side cart and a vision system. The da Vinci Surgical System translates a surgeon's hand movements, which are performed on instrument controls at a console, into corresponding micro-movements of instruments positioned inside the patient through small incisions or ports. The da Vinci Surgical System provides its operating surgeons with control, range of motion, tissue manipulation capability and three-dimensional (3-D), high-definition (HD) vision. Intuitive has four generations of da Vinci Surgical System: the da Vinci Xi Surgical System, the da Vinci Si Surgical System, the da Vinci S Surgical System and the standard da Vinci Surgical System. The Company's instruments and accessories include EndoWrist Instruments and da Vinci Single-Site.

FINANCIAL RATIOS  of  Intuitive Surgical (ISRG)

Valuation Ratios
P/E Ratio 58.4
Price to Sales 15.9
Price to Book 7.4
Price to Tangible Book
Price to Cash Flow 41.2
Price to Free Cash Flow 43.5
Growth Rates
Sales Growth Rate 13.4%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -33.3%
Cap. Spend. - 3 Yr. Gr. Rate -12.5%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 12.9%
Ret/ On Assets - 3 Yr. Avg. 12.3%
Return On Total Capital 14.6%
Ret/ On T. Cap. - 3 Yr. Avg. 14%
Return On Equity 14.6%
Return On Equity - 3 Yr. Avg. 14%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 69.9%
Gross Margin - 3 Yr. Avg. 67.5%
EBITDA Margin 39.7%
EBITDA Margin - 3 Yr. Avg. 34.8%
Operating Margin 34.9%
Oper. Margin - 3 Yr. Avg. 30.5%
Pre-Tax Margin 36.3%
Pre-Tax Margin - 3 Yr. Avg. 31.3%
Net Profit Margin 27.2%
Net Profit Margin - 3 Yr. Avg. 23.9%
Effective Tax Rate 25%
Eff/ Tax Rate - 3 Yr. Avg. 23.7%
Payout Ratio 0%

ISRG stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ISRG stock intrinsic value calculation we used $2704 million for the last fiscal year's total revenue generated by Intuitive Surgical. The default revenue input number comes from 2016 income statement of Intuitive Surgical. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ISRG stock valuation model: a) initial revenue growth rate of 18% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for ISRG is calculated based on our internal credit rating of Intuitive Surgical, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Intuitive Surgical.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ISRG stock the variable cost ratio is equal to 35.9%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $807 million in the base year in the intrinsic value calculation for ISRG stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Intuitive Surgical.

Corporate tax rate of 27% is the nominal tax rate for Intuitive Surgical. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ISRG stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ISRG are equal to 18%.

Life of production assets of 7.5 years is the average useful life of capital assets used in Intuitive Surgical operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ISRG is equal to 3.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $5778 million for Intuitive Surgical - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 111.451 million for Intuitive Surgical is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Intuitive Surgical at the current share price and the inputted number of shares is $41.2 billion.

RELATED COMPANIES Price Int.Val. Rating
JNJ Johnson&Johnso 142.40 147.16  hold
BVX Bovie Medical 3.99 3.23  hold
SYK Stryker 150.49 99.83  sell

COMPANY NEWS

▶ 5 Must-Read Quotes for Robotic Surgery Investors   [Oct-22-17 10:04AM  Motley Fool]
▶ Robots Power Profits at Intuitive Surgical   [Oct-21-17 12:43PM  Motley Fool]
▶ Intuitive Surgical Pops To High As Investors Warm To Metrics   [Oct-20-17 04:52PM  Investor's Business Daily]
▶ Intuitive Surgical: Does It Make the Cut?   [12:47PM  Barrons.com]
▶ Intuitive Surgical Crushes Revenue, Earnings Views, But Shares Dip   [Oct-19-17 05:35PM  Investor's Business Daily]
▶ Why TransEnterix Stock Tanked Today   [05:34PM  Motley Fool]
▶ Intuitive Surgical tops Street 3Q forecasts   [04:23PM  Associated Press]
▶ 3 Stocks to Buy and Forget About   [Oct-18-17 09:29PM  Motley Fool]
▶ A Tiny Upstart Takes Aim at Robotic Surgery   [Oct-17-17 09:01PM  Motley Fool]
▶ Why TransEnterix Stock Is Soaring Today   [12:39PM  Motley Fool]
▶ Surgical robot maker buys $6M Durham building   [10:45AM  American City Business Journals]
▶ Why TransEnterix Is Skyrocketing Today   [10:26AM  Motley Fool]
▶ Better Buy: Intuitive Surgical, Inc. vs. Medtronic plc   [Oct-15-17 09:01AM  Motley Fool]
▶ What Is Intuitive Surgical Incs (ISRG) Share Price Doing?   [Oct-13-17 07:57PM  Simply Wall St.]
▶ Intuitive Surgicals 3Q17 Revenue: Can It Beat the Estimates?   [Oct-12-17 04:06PM  Market Realist]
▶ 3 Top Med-Tech Stocks You Can Buy Right Now   [Oct-08-17 08:19AM  Motley Fool]
▶ 3 Stocks That Could Be Life-Changers   [Oct-06-17 08:15PM  Motley Fool]
▶ If You're in Your 40s, Consider Buying This Stock   [Oct-04-17 09:45PM  Motley Fool]
▶ Does Intuitive Surgical Incs (ISRG) PE Ratio Warrant A Sell?   [Sep-29-17 11:02AM  Simply Wall St.]
▶ A Stellar Start for a Robotics ETF   [Sep-20-17 12:15PM  Investopedia]
▶ 3 Growth Stocks to Buy and Hold for 25 Years   [Sep-19-17 06:04AM  Motley Fool]
▶ iRobot (IRBT) Stock Is Primed for a Rebound and Then Some   [Sep-18-17 04:28PM  InvestorPlace]
▶ 3 Stocks to Hold for the Next Century   [Sep-17-17 12:59PM  Motley Fool]
▶ How Much Higher Can Medtech Climb As Investors Flee Pharma?   [Sep-14-17 05:36PM  Investor's Business Daily]
▶ Five Healthcare Stocks To Buy Before The End Of The Year   [Sep-12-17 09:38AM  Barrons.com]
▶ Why a New Wave of Stock Splits Could Be on the Horizon   [Sep-10-17 08:31AM  Motley Fool]
▶ 3 Reasons Intuitive Surgical, Inc. Stock Could Rise   [Sep-02-17 10:32AM  Motley Fool]
▶ Intuitive Surgical Plans to Expand in Europe and Asia   [Sep-01-17 10:38AM  Market Realist]
▶ Analyzing Intuitive Surgicals 2Q17 Results   [09:09AM  Market Realist]
▶ 2 Reasons Intuitive Surgical, Inc. Stock Could Fall   [Aug-31-17 07:33PM  Motley Fool]
▶ 3 Stocks to Buy for a Better Tomorrow   [Aug-29-17 03:29PM  Motley Fool]
▶ The 5 Best Silicon Valley Stocks to Buy in 2017   [Aug-25-17 07:23AM  Motley Fool]
▶ 5 Companies Hit 52-Week Highs   [Aug-22-17 01:31PM  GuruFocus.com]
▶ How Intuitive Surgical, Inc. Makes Most of Its Money   [Aug-12-17 02:07PM  Motley Fool]
▶ [$$] Auris Surgical Robotics Banks $280 Million   [Aug-03-17 09:46PM  The Wall Street Journal]
▶ 3 Companies Building the World of Tomorrow   [Aug-02-17 11:00AM  Motley Fool]
▶ 3 Stocks With Tesla-like Return Potential   [Aug-01-17 07:15AM  Motley Fool]
Financial statements of ISRG
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.